MyFinsight
Home
Blog
About
Contact
Net change in cash,
cash equivalents and...
-$88,741K
(5.46%↑ Y/Y)
Stock-based compensation
$22,215K
(-38.39%↓ Y/Y)
Depreciation and
amortization
$19,673K
(1.77%↑ Y/Y)
Other receivables and
assets
-$14,746K
(-204.73%↓ Y/Y)
Lease expense
$5,243K
(-14.47%↓ Y/Y)
Accounts payable
$2,070K
(-43.93%↓ Y/Y)
Other, net
-$1,674K
(62.00%↑ Y/Y)
Accrued development
expense
$730K
(21.87%↑ Y/Y)
Net cash used in
operating activities
-$81,101K
(38.54%↑ Y/Y)
Effect of exchange rate
changes on cash, cash...
-$3,832K
(-179.29%↓ Y/Y)
Net cash provided by
(used in) financing...
-$3,470K
(-108.56%↓ Y/Y)
Net cash used in
investing activities
-$338K
(95.35%↑ Y/Y)
Canceled cashflow
$66,351K
Net loss
-$117,504K
(41.97%↑ Y/Y)
Repayment of long-term
debt and finance...
$2,208K
(7.87%↑ Y/Y)
Equity incentive plans
-$1,262K
Purchases of property and
equipment
$258K
(-85.92%↓ Y/Y)
Purchase of an intangible
asset
$80K
Accrued expenses and
other current...
-$18,451K
(30.61%↑ Y/Y)
Lease liabilities
-$4,652K
(19.24%↑ Y/Y)
Deferred income taxes
-$4,597K
Unearned revenue
-$2,248K
(76.97%↑ Y/Y)
Back
Back
Cash Flow
6556d670e8da976dc91d11c4_Recursion Logo Horizontal Black-svg
RECURSION PHARMACEUTICALS, INC. (RXRX)
6556d670e8da976dc91d11c4_Recursion Logo Horizontal Black-svg
RECURSION PHARMACEUTICALS, INC. (RXRX)
source: myfinsight.com